| Quantity: | |
|---|---|
Complementary mechanisms – IL-31/wound model mimics wound healing-associated itch; AEW model mimics dry skin and barrier disruption-induced itch.
Quantifiable endpoint – Scratch bouts (scratching behavior) recorded and quantified over defined time periods.
Comprehensive endpoints – Scratch behavior, dendritic cell infiltration (IL-31 model), skin histopathology, IL-31 levels in skin (AEW model).
Translational value – Ideal for testing antihistamines, IL-31 blockers, JAK inhibitors, TRPV1 antagonists, and other anti-pruritic agents.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
IL-31& wound Induced C57BL/6 pruritus Model
AEW Induced C57BL/6 Pruritus Model
• Efficacy testing of anti-pruritic agents: antihistamines (cetirizine, fexofenadine), IL-31 blockers (nemolizumab), JAK inhibitors (tofacitinib, baricitinib), TRPV1 antagonists
• Target validation for IL-31 pathway, skin barrier function, and neuro-immune interactions
• Biomarker discovery (IL-31, scratch counts, skin barrier markers)
• Mechanism of action (MOA) studies for pruritus therapeutics
• IND-enabling pharmacology and toxicology studies
Parameter | IL-31 & Wound Induced Model | AEW Induced Model |
Species/Strain | C57BL/6 mouse | C57BL/6 mouse |
Induction method | Cutaneous wound + intradermal IL-31 injection | Topical acetone/ether/water (AEW) application on back skin (daily for 2–5 days) |
Study duration | 1–7 days post-wound/IL-31 | 2–7 days post-AEW treatment |
Key endpoints | Scratch bouts (30–60 min), dendritic cell infiltration in skin (flow cytometry/IHC) | Scratch bouts, skin histopathology (HE), IL-31 levels in skin (ELISA), clinical photographs |
Data package | Raw data, analysis reports, behavioral data (scratch video), histology slides, ELISA results, bioinformatics (optional) | |
Q: What are the differences between the two pruritus models?
A: The IL-31 & wound model mimics wound healing-associated itch, driven by IL-31 and inflammatory cell infiltration. The AEW model induces dry skin and barrier disruption, leading to itch through xerosis and increased IL-31 production. Choose based on your therapeutic target (IL-31 pathway vs. skin barrier restoration).
Q: How is scratching behavior quantified?
A: Scratch bouts are recorded using video monitoring systems (manual or automated). Typically, a scratch bout is defined as one or more scratching motions directed at the affected area (wound or back skin) over a defined time period (e.g., 30–60 minutes).
Q: Can these models be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different IL-31 doses, AEW treatment schedules)?
A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Both models are acute (1–7 days), allowing rapid screening of anti-pruritic compounds. Studies are typically completed within 5–7 days post-induction.
